These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26018435)

  • 1. Generalized Degenerative Joint Disease in Osteoprotegerin (Opg) Null Mutant Mice.
    Bolon B; Grisanti M; Villasenor K; Morony S; Feige U; Simonet WS
    Vet Pathol; 2015 Sep; 52(5):873-82. PubMed ID: 26018435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
    Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
    Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin deficiency leads to deformation of the articular cartilage in femoral head.
    Liu Y; Ge J; Chen D; Weng Y; Du H; Sun Y; Zhang Q
    J Mol Histol; 2016 Oct; 47(5):475-83. PubMed ID: 27541035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation.
    van Lent PL; Grevers L; Lubberts E; de Vries TJ; Nabbe KC; Verbeek S; Oppers B; Sloetjes A; Blom AB; van den Berg WB
    Arthritis Rheum; 2006 Dec; 54(12):3868-77. PubMed ID: 17133594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice.
    Sakakura Y; Tsuruga E; Irie K; Hosokawa Y; Nakamura H; Yajima T
    J Anat; 2005 Oct; 207(4):325-37. PubMed ID: 16191162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis.
    Neumann T; Oelzner P; Petrow PK; Thoss K; Hein G; Stein G; Bräuer R
    Inflamm Res; 2006 Jan; 55(1):32-9. PubMed ID: 16429254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis.
    Kadri A; Ea HK; Bazille C; Hannouche D; Lioté F; Cohen-Solal ME
    Arthritis Rheum; 2008 Aug; 58(8):2379-86. PubMed ID: 18668550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated cartilage resorption by chondroclasts during bone fracture healing in osteoprotegerin-deficient mice.
    Ota N; Takaishi H; Kosaki N; Takito J; Yoda M; Tohmonda T; Kimura T; Okada Y; Yasuda H; Kawaguchi H; Matsumoto M; Chiba K; Ikegami H; Toyama Y
    Endocrinology; 2009 Nov; 150(11):4823-34. PubMed ID: 19819969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis.
    Shimizu S; Asou Y; Itoh S; Chung UI; Kawaguchi H; Shinomiya K; Muneta T
    Arthritis Rheum; 2007 Oct; 56(10):3358-65. PubMed ID: 17907189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.
    Stolina M; Dwyer D; Ominsky MS; Corbin T; Van G; Bolon B; Sarosi I; McCabe J; Zack DJ; Kostenuik P
    J Immunol; 2007 Dec; 179(11):7497-505. PubMed ID: 18025194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
    Kong YY; Feige U; Sarosi I; Bolon B; Tafuri A; Morony S; Capparelli C; Li J; Elliott R; McCabe S; Wong T; Campagnuolo G; Moran E; Bogoch ER; Van G; Nguyen LT; Ohashi PS; Lacey DL; Fish E; Boyle WJ; Penninger JM
    Nature; 1999 Nov; 402(6759):304-9. PubMed ID: 10580503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.
    Campagnuolo G; Bolon B; Feige U
    Arthritis Rheum; 2002 Jul; 46(7):1926-36. PubMed ID: 12124878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in cultured equine articular cells.
    Byron CR; Barger AM; Stewart AA; Pondenis HC; Fan TM
    Am J Vet Res; 2010 Jun; 71(6):615-22. PubMed ID: 20513175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
    Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
    Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis.
    Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA
    Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin-deficient male mice as a model for severe alveolar bone loss: comparison with RANKL-overexpressing transgenic male mice.
    Koide M; Kobayashi Y; Ninomiya T; Nakamura M; Yasuda H; Arai Y; Okahashi N; Yoshinari N; Takahashi N; Udagawa N
    Endocrinology; 2013 Feb; 154(2):773-82. PubMed ID: 23291450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.